218 related articles for article (PubMed ID: 16925454)
1. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA
J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454
[TBL] [Abstract][Full Text] [Related]
2. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
[TBL] [Abstract][Full Text] [Related]
3. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
[TBL] [Abstract][Full Text] [Related]
4. Quality measure attainment in patients with type 2 diabetes mellitus.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Sheng Duh M; Lefebvre P
Am J Manag Care; 2014 Jan; 20(1 Suppl):s5-15. PubMed ID: 24512194
[TBL] [Abstract][Full Text] [Related]
5. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study.
Huizinga MM; Roumie CL; Greevy RA; Liu X; Murff HJ; Hung AM; Grijalva CG; Griffin MR
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1108-12. PubMed ID: 20878643
[TBL] [Abstract][Full Text] [Related]
6. Oral antidiabetic medication adherence and glycemic control in managed care.
Rozenfeld Y; Hunt JS; Plauschinat C; Wong KS
Am J Manag Care; 2008 Feb; 14(2):71-5. PubMed ID: 18269302
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
9. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.
Herman WH; Buse JB; Arakaki RF; Dungan KM; Jiang HH; Jacobson JG; Fahrbach JL
Endocr Pract; 2011; 17(4):563-7. PubMed ID: 21550959
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.
Rendell MS; Glazer NB; Ye Z
J Diabetes Complications; 2003; 17(4):211-7. PubMed ID: 12810245
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease.
Spence MM; Makarem AF; Reyes SL; Rosa LL; Nguyen C; Oyekan EA; Kiyohara AT
J Manag Care Spec Pharm; 2014 Oct; 20(10):1036-45. PubMed ID: 25278326
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
[TBL] [Abstract][Full Text] [Related]
13. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
Phung OJ; Sobieraj DM; Engel SS; Rajpathak SN
Diabetes Obes Metab; 2014 May; 16(5):410-7. PubMed ID: 24205921
[TBL] [Abstract][Full Text] [Related]
14. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.
Alvarez Guisasola F; Tofé Povedano S; Krishnarajah G; Lyu R; Mavros P; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():25-32. PubMed ID: 18435671
[TBL] [Abstract][Full Text] [Related]
17. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
Duckworth W; Marcelli M; Padden M; Kellick K; Duhancik T; Wilhardt M; Colgan K; Romie A
J Manag Care Pharm; 2003; 9(3):256-62. PubMed ID: 14613469
[TBL] [Abstract][Full Text] [Related]
18. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
Thayer S; Arondekar B; Harley C; Darkow TE
Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
[TBL] [Abstract][Full Text] [Related]
19. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
